Market Overview

Navidea Biopharmaceuticals Announces Details of 2018 Annual General Meeting

Share:

Michael Goldberg, M.D. Resigns as Chief Executive Officer and
Director of Navidea

Jed A. Latkin, Chief Financial Officer and Chief Operating Officer,
Appointed Interim Chief Executive Officer and Director

Conference call to take place August 16th,
2018 at 5:00pm EDT

As previously announced, Navidea Biopharmaceuticals, Inc. (NYSE
American: NAVB) ("Navidea" or the "Company"), a company focused on the
development of precision immunodiagnostic agents and immunotherapeutics,
will host a conference call today, August 16, 2018, at 5:00pm EDT to
discuss details of the Annual Meeting for its shareholders, to be held
today in Fort Lee, New Jersey under the chairmanship of Michael Rice,
director of Navidea.

During the meeting, management will provide updates on the following:

  • The Rheumatoid Arthritis and Activated Macrophage Data has been
    submitted to the U.S. Food and Drug Administration ("FDA"); a meeting
    with the FDA is now confirmed for late September.
  • The terms of Dr. Goldberg's separation from Navidea.
  • The leadership transition plan, including Mr. Jed A. Latkin's new role
    as Interim Chief Executive Officer and member of the board, effective
    August 14, 2018.
  • The business plan moving forward for Navidea's subsidiary, Macrophage
    Therapeutics, Inc. ("MT"), which will now be led by Dr. Goldberg.

Going forward, Dr. Goldberg will serve as Chief Executive Officer of MT
and will concentrate all of his attention and efforts on progressing the
developments taking place. In this role, Dr. Goldberg will focus on
addressing MT's long-term funding needs as well as progressing its
clinical pipeline.

"Navidea is grateful to Dr. Goldberg for his extensive contributions to
the Company over the last 5 years, helping to build its leadership
position in precision medicine," said Mr. Jed A. Latkin, Interim Chief
Executive Officer. "We believe this business transition will allow
Navidea and our subsidiary, Macrophage Therapeutics, to focus their
efforts on advancing the novel pipelines and delivering on our mission.
Our goal throughout these corporate changes is to consistently create
long-term value for our stakeholders as we shift the focus of the
business and strive towards improving patient care. Furthermore, we are
extremely excited that the FDA has granted us a meeting request in late
September. We look forward to advancing our second product to
commercialization."

Jed Latkin has served as Navidea's Chief Financial Officer and Chief
Operating Offer since 2016. Previously, he was a Portfolio Manager at
Nagel Avenue Capital from 2010 to 2016, at ING Investment Management
from 2006 to 2010, and at Morgan Stanley from 2002 to 2006.

Conference Call Details

Investors and the public are invited to access the live audio webcast
through the link below. Participants who would like to ask questions
during the question and answer session must participate by telephone.
Participants are encouraged to log-in and/or dial-in fifteen minutes
before the conference call begins.

Event:     Annual Meeting Discussion and Update on Current Corporate Events and
Outlook
Date: Thursday, August 16, 2018
Time: 5:00 pm (Eastern Time)
U.S. & Canada Dial-in: 877-407-0312
Conference ID: 13682395

Webcast:

https://webcasts.eqs.com/navidea20180816

The presentations to shareholders at the Annual Meeting as well as the
Webcast of the Annual Meeting Discussion and Update on Current Corporate
Events and Outlook Conference call will be posted on August 16, 2018 on
the corporate website.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of disease
and enable better diagnostic accuracy, clinical decision-making, and
targeted treatment. Navidea's Manocept platform is predicated on the
ability to specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the molecular
backbone of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel products and advancing
the Company's pipeline through global partnering and commercialization
efforts.

For more information, please visit www.navidea.com.

Forward-Looking Statements

This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. We have based these forward-looking statements largely
on our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including, among other things: the timing
of, and our ability to, move forward with our business plans, including
as they relate to Macrophage Therapeutics, Inc., general economic and
business conditions, both nationally and in our markets; our history of
losses and uncertainty of future profitability; the final outcome of the
CRG litigation in Texas; our ability to successfully complete research
and further development of our drug candidates; the timing, cost and
uncertainty of obtaining regulatory approvals of our drug candidates;
our ability to successfully commercialize our drug candidates; our
expectations and estimates concerning future financial performance,
financing plans and the impact of competition; our ability to raise
capital sufficient to fund our development and commercialization
programs; our ability to implement our growth strategy; anticipated
trends in our business; advances in technologies; and other risk factors
set forth in this report and detailed in our most recent Annual Report
on Form 10-K and other SEC filings. You are urged to carefully review
and consider the disclosures found in our SEC filings, which are
available at 
www.sec.gov or
at 
http://ir.navidea.com.

Investors are urged to consider statements that include the words
"will," "may," "could," "should," "plan," "continue," "designed,"
"goal," "forecast," "future," "believe," "intend," "expect,"
"anticipate," "estimate," "project," and similar expressions, as well as
the negatives of those words or other comparable words, to be uncertain
forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be incorrect. We undertake no
obligation to update publicly or revise any forward-looking statements,
whether as a result of new information, future events or otherwise after
the date of this report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report may
not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.

View Comments and Join the Discussion!